iRadimed(IRMD) - 2025 Q4 - Annual Report

Regulatory Compliance - The company is subject to extensive government regulation, particularly from the FDA, which could result in delays or increased costs during product development and approval [202]. - Compliance with evolving domestic and international laws regarding AI could impose significant costs and obligations on the company [199]. - The company is subject to healthcare fraud and abuse regulations that could result in significant liability and require changes to business practices [216]. - Compliance with FDA regulations is subject to continual review and can result in sanctions, affecting sales and profitability [223]. - The FDA's guidance on infusion pumps has increased pre-market requirements, leading to higher costs and longer approval times for new products [222]. - Compliance with public company regulations may strain resources and divert management's attention from core business operations [250]. - The company is subject to evolving laws and regulations, increasing compliance costs and potentially diverting management's focus from revenue-generating activities [251]. Financial Performance and Risks - The company is exposed to risks associated with changing economic conditions, including interest rates and inflation, which could adversely affect financial results [200]. - The company carries third-party product liability insurance with a maximum coverage of $5 million, but faces significant deductibles that could impact financial condition [211]. - The company faces potential product liability claims that could materially affect profitability and financial condition [209]. - The company believes it has adequate capital for operations over the next 12 months, but may need to raise additional funds [247]. - The company may face significant fluctuations in stock price due to various factors, including product success and regulatory changes [241]. - Market fluctuations have historically impacted small capitalization medical device companies, potentially leading to declines in stock price and increased litigation risks [256]. International Operations - Sales to customers outside of the U.S. accounted for approximately 16% of net revenues in 2025, with expectations for future growth from international markets [207]. - The company operates in approximately 80 countries, with most transactions in U.S. Dollars, exposing it to foreign currency exchange risks [333]. - Fluctuations in the Japanese Yen could affect the company's net income, with a 10% change in the Yen's strength resulting in an immaterial impact on net income for the year ended December 31, 2025 [334]. Intellectual Property and Innovation - The company relies on a combination of patents and trade secrets to protect its intellectual property, but there is no guarantee these protections will be effective [226]. - Patent litigation could result in substantial expenses and may disrupt product commercialization efforts [233]. - The development and use of AI technologies present risks that could impact operations and lead to legal or regulatory challenges [198]. Corporate Governance - As of December 31, 2025, the founder owns approximately 35% of the company's outstanding common stock, allowing significant influence over stockholder approval matters [253]. - The company faces increased visibility and potential litigation risks as a public entity, which could adversely affect its business and profitability [254]. Dividends - The Board of Directors declared a quarterly cash dividend of $0.20 per share, but future dividends are not guaranteed [245].